Semaglutide denied for failing step therapy by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Step Therapy for Semaglutide — and How to Win the Appeal

Step-therapy (sometimes called "fail-first") requirements from Blue Cross Blue Shield are a frequent barrier for patients prescribed semaglutide. The plan wants documented evidence that you tried — and inadequately responded to, or could not tolerate — one or more less costly or preferred medications before semaglutide will be covered. This denial type has a high reversal rate when the prior-treatment record is thorough and the prescriber's letter directly addresses each required step.

## Why This Denial Happens

BCBS places semaglutide at a higher step in its utilization management hierarchy because of its cost relative to other agents in its therapeutic class. The plan's coverage criteria require evidence of prior therapy before it will authorize coverage. Gaps in the submitted documentation — missing dates, undocumented outcomes, or an unstated clinical reason for skipping a step — are the most common triggers for denial at this stage.

## Your Federal Appeal Rights

• Internal appeal: File within 180 days of the denial notice. Standard decisions within 30–60 days; expedited decisions within 72 hours.
• Step-therapy exception: Many states have enacted step-therapy exception laws requiring plans to waive the step requirement when a prior step agent was contraindicated, previously failed, or is clinically inappropriate. Identify whether your state has such a law and invoke it by name in your appeal.
• External review (ACA §2719): After the internal appeal, request independent external review within approximately 4 months of the final denial. External reviewers are not bound by BCBS's formulary tier structure — they assess clinical appropriateness.
• ERISA §503: For employer self-funded plans, full-and-fair review applies, with federal court as a backstop.
• Expedited option: Available if your condition is urgent or if delay would seriously jeopardize your health.

## Documentation to Gather

1. Prior-therapy records: Pharmacy dispensing records, chart notes, and prescriber attestations for every agent required by BCBS's step policy — including the exact dates of use, doses tried, and documented outcomes (inadequate response, adverse effect, clinical contraindication). 2. Step-skip justification: If a required step agent was never tried, your prescriber must document in writing why it was not clinically appropriate — this is where the prescriber's letter is most critical. 3. Current clinical status: Chart documentation of your present condition severity and why delayed or substituted treatment poses a clinical risk. 4. Prescriber medical-necessity letter: A structured letter that addresses each of BCBS's step-therapy criteria in order, cites the FDA-approved prescribing information for semaglutide, and references the applicable professional guideline organization (such as the ADA or relevant obesity-medicine society). 5. BCBS step-therapy policy: Request the full text so your appeal addresses every criterion.

## Criteria-Mapping Structure

| BCBS Step Requirement | Your Evidence | |---|---| | [Step 1 agent required by policy] | [Dates tried, outcome, chart note reference] | | [Step 2 agent required by policy] | [Dates tried, outcome, or documented clinical reason not tried] | | [Criteria for advancing to semaglutide] | [Chart fact confirming eligibility per FDA label and guidelines] |

Submit all pharmacy records and chart notes as labeled exhibits. The cover letter should cite the specific denial date and reference both the step-therapy exception framework and the medical-necessity basis for semaglutide.